Apyx Medical, Q3 2026 Earnings Call Transcript

Apyx Medical’s third-quarter revenue rose 9% year over year, led by AYON sales in the U.S. and Renuvion internationally; Surgical Aesthetics grew 17%, while OEM revenue fell as the company shifts focus to aesthetics. Management says AYON’s power-liposuction launch is gaining positive surgeon feedback and sees the platform as a multiyear growth driver, with international expansion dependent on regulatory approvals. The company also views patients losing weight with GLP-1 drugs as a long-term opportunity for body-contouring procedures. Apyx reported positive adjusted EBITDA for the quarter and positive EBITDA over the trailing 12 months, reaffirmed 2026 revenue guidance of $59–60 million, and lowered its operating-expense target. Gross-margin guidance is now 63–64%; management expects OEM revenue to decline for the year.